DEM BioPharma
PrivateLast Round
Series A
Jun 23, 2022
Total Funding Raised
$70M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
DEM BioPharma operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in June 2022.
DEM BioPharma is a biotechnology company that develops innovative immunotherapeutics targeting novel signals on cancer cells and macrophages to eliminate solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DEM BioPharma Comparables
Compare DEM BioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pheast Therapeutics | 87% | |
| ALX Oncology | 75% | |
| ImmuneOncia Therapeutics | 74% |
For institutional investors. Book with your work email.
DEM BioPharma Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
DEM BioPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dean Capital Investments Management | Series A |
| Alexandria Venture Investments | Series A |
| Emerson Collective | Series A |
| Astellas Venture Management | Series A |
| Pfizer Ventures | Series A |
| Pfizer | Series A |
| Longwood Fund | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 46% MoM.
- Jul 24, 2026
Monthly visitors increased 352% MoM.
For institutional investors. Book with your work email.
DEM BioPharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about DEM BioPharma's valuation, stock price, and market status.
Is DEM BioPharma a public or private company?
DEM BioPharma is a private company.
What is the current stock price of DEM BioPharma?
DEM BioPharma is a private company, so its shares have no public market price. Caplight tracks DEM BioPharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is DEM BioPharma worth (valuation)?
Valuation information for DEM BioPharma is not publicly available.
Can I buy DEM BioPharma stock?
DEM BioPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was DEM BioPharma's last funding round?
DEM BioPharma's most recent funding round was Series A on June 23, 2022.
Who are the main investors in DEM BioPharma?
Key investors in DEM BioPharma include Longwood Fund, Alta Partners.
Will DEM BioPharma IPO soon?
No public IPO plans have been announced for DEM BioPharma.
How can I track DEM BioPharma secondary market activity?
Caplight tracks bids, offers, and trades in DEM BioPharma's shares on secondary markets.